Investigational drug · Phase 3
TLL-018
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
6 still active
All registered trials
14
Any phase or sponsor naming "TLL-018"
First trial start
2023
Jan 19, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TLL-018", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Spontaneous Urticaria (CSU)
- Rheumatoid Arthritis
- Chronic Spontaneous Urticaria
- Rheumatoid Arthritis (RA)
- Atopic Dermatitis (AD)
- Plaque Psoriasis
Approved drugs for the same conditions: Rheumatoid arthritis · Plaque psoriasis · Atopic dermatitis (eczema) · Chronic hives (urticaria) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "TLL-018" as an intervention, largest first.
- A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDsPivotal-lookingCompleted
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT06020144 · 459 participants · Start Nov 15, 2023 · Primary completion Jan 15, 2026
Drug: TLL-018; Tofacitinib · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsPivotal-lookingActive, not recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT06396026 · 440 participants · Start Mar 27, 2024 · Primary completion Oct 23, 2025
Drug: TLL-018 tablets; Placebo tablets · For: Chronic Spontaneous Urticaria
Sites: Nanjing, China
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT07784816 · 390 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 30, 2029
Drug: TLL-018 tablets; TLL-018 tablets and 2 more · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid ArthritisPivotal-lookingActive, not recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT06887127 · 350 participants (planned) · Start Mar 10, 2025 · Primary completion Dec 31, 2026
Drug: TLL-018 · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsPivotal-lookingNot yet recruiting
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT07764003 · 140 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 31, 2027
Drug: TLL-018 tablets; TLL-018 tablets and 1 more · For: Chronic Spontaneous Urticaria (CSU)
- The Safety and Efficacy of TLL-018 in Active Rheumatoid ArthritisPivotal-lookingCompleted
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT05133297 · 101 participants · Start Feb 16, 2022 · Primary completion Dec 19, 2022
Drug: TLL-018; TLL-018 and 2 more · For: Rheumatoid Arthritis
Sites: Beijing, China
- A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy ParticipantsPivotal-lookingCompleted
TLL Pharmaceutical, LLCIndustry
NCT04243083 · 100 participants · Start Jan 26, 2020 · Primary completion Dec 23, 2020
Drug: TLL018 tablet, placebo · For: Healthy
Sites: Secaucus, New Jersey
- TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDsEnrolling by invitation
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT07748728 · 90 participants (planned) · Start Sep 18, 2026 · Primary completion Jul 31, 2027
Drug: TLL-018; Placebo · For: Rheumatoid Arthritis (RA)
Sites: Beijing, China
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT05772520 · 82 participants · Start Jan 19, 2023 · Primary completion Dec 1, 2024
Drug: TLL018 tablets · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Beverly Hills, California; Los Angeles, California · 35 sites in all
Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
NCT05342428 · 73 participants · Start Jun 10, 2022 · Primary completion Aug 30, 2023
Drug: TLL018 tablets · For: Moderate to Severe Plaque Psoriasis
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Correction: Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.
· Br J Dermatol 2026
- Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety.
Costa L, Caso F, Maione F, et al. · Drug Des Devel Ther 2026
- Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.
Yao X, Liu Y, Luo Y, et al. · Br J Dermatol 2026
- The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
Burshtein J, Schlesinger T · J Clin Aesthet Dermatol 2026
- Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study.
Chen JQ, Zheng M, Yin WH, et al. · Br J Dermatol 2025
- Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.
Asero R, Calzari P, Vaienti S, et al. · Pharmaceuticals (Basel) 2024
Also in development for Chronic Spontaneous Urticaria (CSU)
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- MG-K10 Humanized Monoclonal AntibodyPhase 34 trials
Shanghai Mabgeek Biotech.Co.Ltd · Atopic Dermatitis, Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU)
- LesigerceptPhase 21 trial
Yuhan Corporation · Allergic Diseases, Chronic Spontaneous Urticaria (CSU)
- NN2802Phase 21 trial
Novelty Nobility, Inc. · Healhty, Chronic Spontaneous Urticaria (CSU)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.